Potters 200 years heritage set for a bright future, naturally
For over 200 years Potter’s has been making and selling herbal remedies. From a single shop in London in 1812, it has grown into a much loved British brand. It is the oldest herbal medicines manufacturer in the UK and has an extensive range of well-established products including treatments for coughs and colds, pain to joint care, gastro-intestinal disorders and women’s health. All the Potter’s Herbals products are approved by the government’s Medicines and Healthcare products Regulatory Agency (MHRA) under the Traditional Herbal Registration scheme (THR).
In addition to this range of products, Potters features brands like Red Kooga®, Seatone®, Calcia™ as well as Equazen™ one of the world’s leading evidence-based omega supplements for all family ages. Potters products are sold throughout the UK by major retailers such as Boots and Holland & Barrett as well as pharmacy and health food outlets.
The Equazen™ brand is backed by robust specific clinical research and in recent years has expanded to deliver brain health solutions to various patient groups. The brand also includes the international product Equazen™ eye-q®.
With subsidiary companies in Europe, Asia and America, the SFI Group draws on more than 70 years of international experience in the high-quality natural health sector. The SFI Group is committed to providing clinically proven natural health solutions to health professionals and consumers worldwide.
Nigel Pollard, Chief Executive of SFI, commented: “Potters is a strong and iconic brand in the natural medicine sector. Together with its history of over two centuries, Potters will bring to the SFI Group an excellent team and an extensive portfolio of tried and trusted products. These products and the business platform in the UK and Europe are an excellent fit for SFI as we seek to build our world leading position in the field of clinically-proven natural medicine.”
The transaction has now been completed.
For further information, please contact:
Media Relations – SFI:
Elisa Ranieri, Head of Marketing EMEA
Tel.: +41 91 610 3724
E-mail: ranieri@ginsana.ch
Media Relations – SFI Potters:
Jane Wragg, 01942 219964; jane.wragg@viforpharma.com
Nicky Smith, 0207 052 8850; nicky.smith@nexsuspr.com
Emma Fox, on 020 7052 8853; emma.fox@nexuspr.com
Soho Flordis International (SFI), an Australian registered company, is an international provider of clinically proven natural medicines. SFI is committed to identifying and developing leading natural medicines with the best evidence of effectiveness, quality and safety, and marketing them around the world through healthcare professionals with the endorsement of world class opinion leaders.
For more information about SFI, please visit www.sfihealth.com
Potter’s Herbals has a long and proud heritage in making traditional herbal medicines of the highest quality, they are fully licensed and carry the Traditional Herbal Registration (THR) to comply with the UK government’s Medicines and Healthcare products Regulatory Agency (MHRA). Since 1812 when Henry Potter first opened his herbalist business in London, the name Potter’s has been synonymous with all that is best in herbal medicines. Almost all of our herbal formulations are made with a careful blend of multi-ingredients to harness the individual power of plants and provide a more beneficial synergistic effect.
For information about Potters, please visit: www.pottersherbals.co.uk
EQUAZENTM is a dietary supplement with a specific combination of omega-3 and omega-6 fatty acids from natural sources (fish oil and evening primrose oil). EQUAZEN’s unique formulation has been tested in clinical trials and showed efficacy in brain function, particularly in children and adolescents with learning disabilities, cognitive & developmental disorders such as dyslexia, dyspraxia, or ADHD-symptoms1,2,3,4.
For more information about EQUAZENTM please visit www.EQUAZEN.com
1. M. Johnson, S. Östlund, G. Fransson, B. Kadesjö, C.Gillberg,Omega-3/omega-6 fatty acids for attention deficit hyperactivity disorder, J. Atten. Disord. 12 (2008)394–401.
2. A.J. Richardson, P. Montgomery, The Oxford–Durham study: a randomised, controlled trial of dietary supplementation with fatty acids in children with developmental coordination disorder, Pediatrics 115(2005)1360–1366.
3. N. Sinn, J. Bryan, Effect of supplementation with polyunsaturated fatty acids and micronutrients on ADHD-related problems with attention and behavior, J. Dev. Behav. Pediatr. 28(2007)82–91.
4. N. Sinn, J. Bryan, C. Wilson, Cognitive effects of polyunsaturated fatty acids in children with attention deficit hyperactivity disorder symptoms: a randomised controlled trial, Prostaglandins Leukot. Essent.FattyAcids78 (2008)311–326.